Jump to content

D-15414

From Wikipedia, the free encyclopedia
D-15414
Identifiers
  • 1-ethyl-2-(4-hydroxyphenyl)-3-methylindol-5-ol
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H17NO2
Molar mass267.328g·mol−1
3D model (JSmol)
  • CCN1C2=C(C=C(C=C2)O)C(=C1C3=CC=C(C=C3)O)C
  • InChI=1S/C17H17NO2/c1-3-18-16-9-8-14(20)10-15(16)11(2)17(18)12-4-6-13(19)7-5-12/h4-10,19-20H,3H2,1-2H3
  • Key:BXTNOIWYTWIPEL-UHFFFAOYSA-N

D-15414is anonsteroidalweakestrogenof the2-phenylindolegroup which was never marketed.[1][2]It is the majormetaboliteof theselective estrogen receptor modulator(SERM)zindoxifene(D-16726).[3]D-15414 has highaffinityfor theestrogen receptor(ER) and inhibits the growth of ER-positiveMCF-7breast cancercellsin vitro.[3]However, contradictorily, subsequent research found that the drug produced fullyestrogeniceffectsin vitrosimilarly to but less actively thanestradiol,with noantiestrogenicactivity observed.[1][2]The reason for the discrepancy between the findings is unclear, though may be due tomethodology.[2]The unexpected estrogenic activity of D-15414 may be responsible for the failure of zindoxifene inclinical trialsas a treatment forbreast cancer.[1][4]

References

[edit]
  1. ^abcJordan VC, Tormey DC (1988). "Antiestrogen Therapy for Breast Cancer".Endocrine Therapies in Breast and Prostate Cancer.Cancer Treatment and Research. Vol. 39. pp. 97–110.doi:10.1007/978-1-4613-1731-9_7.ISBN978-1-4612-8974-6.PMID2908611.
  2. ^abcRobinson SP, Koch R, Jordan VC (February 1988). "In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo".Cancer Research.48(4): 784–787.PMID3338076.
  3. ^abvon Angerer E, Prekajac J, Berger M (April 1985). "The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors".European Journal of Cancer & Clinical Oncology.21(4): 531–537.doi:10.1016/0277-5379(85)90048-3.PMID3924626.
  4. ^Maximov PY, McDaniel RE, Jordan VC (23 July 2013).Tamoxifen: Pioneering Medicine in Breast Cancer.Springer Science & Business Media. pp. 170–.ISBN978-3-0348-0664-0.